The aim of the consensus process was to develop a practical, evidence-based statement, in line with existing NICE guidance that would help GPs to identify the risk status of patients with osteoarthritis and, where appropriate, to provide the most effective appropriate tNSAID or COX-2 treatment for them. This evidence concerns the gene PTGS2 and osteoarthritis.